特殊病理类型子宫内膜癌(special type endometrial carcinoma,STEC)是一类病死率较高的妇科恶性肿瘤,相较常见的子宫内膜样腺癌,STEC进展快、复发率高,且具有显著组织异型性,传统病理分型无法满足临床需要。近年来提出的TCGA等分子分型...特殊病理类型子宫内膜癌(special type endometrial carcinoma,STEC)是一类病死率较高的妇科恶性肿瘤,相较常见的子宫内膜样腺癌,STEC进展快、复发率高,且具有显著组织异型性,传统病理分型无法满足临床需要。近年来提出的TCGA等分子分型对STEC的诊治具有重要意义,本文就分子分型在浆液性癌、透明细胞癌、癌肉瘤、去/未分化癌和高级别不明确子宫内膜癌五类STEC中的研究进展进行综述,包括分子分型在STEC诊断和鉴别、靶向药物研发、疗效预测及预后中的应用,以期为临床合理应用分子分型提供参考。展开更多
Gene editing has recently emerged as a promising technology to engineer genetic modifications precisely in the genome to achieve long-term relief from corneal disorders.Recent advances in the molecular biology leading...Gene editing has recently emerged as a promising technology to engineer genetic modifications precisely in the genome to achieve long-term relief from corneal disorders.Recent advances in the molecular biology leading to the development of clustered regularly interspaced short palindromic repeats(CRISPRs) and CRISPR-associated systems,zinc finger nucleases and transcription activator like effector nucleases have ushered in a new era for high throughput in vitro and in vivo genome engineering.Genome editing can be successfully used to decipher complex molecular mechanisms underlying disease pathophysiology,develop innovative next generation gene therapy,stem cell-based regenerative therapy,and personalized medicine for corneal and other ocular diseases.In this review we describe latest developments in the field of genome editing,current challenges,and future prospects for the development of personalized genebased medicine for corneal diseases.The gene editing approach is expected to revolutionize current diagnostic and treatment practices for curing blindness.展开更多
文摘特殊病理类型子宫内膜癌(special type endometrial carcinoma,STEC)是一类病死率较高的妇科恶性肿瘤,相较常见的子宫内膜样腺癌,STEC进展快、复发率高,且具有显著组织异型性,传统病理分型无法满足临床需要。近年来提出的TCGA等分子分型对STEC的诊治具有重要意义,本文就分子分型在浆液性癌、透明细胞癌、癌肉瘤、去/未分化癌和高级别不明确子宫内膜癌五类STEC中的研究进展进行综述,包括分子分型在STEC诊断和鉴别、靶向药物研发、疗效预测及预后中的应用,以期为临床合理应用分子分型提供参考。
文摘Gene editing has recently emerged as a promising technology to engineer genetic modifications precisely in the genome to achieve long-term relief from corneal disorders.Recent advances in the molecular biology leading to the development of clustered regularly interspaced short palindromic repeats(CRISPRs) and CRISPR-associated systems,zinc finger nucleases and transcription activator like effector nucleases have ushered in a new era for high throughput in vitro and in vivo genome engineering.Genome editing can be successfully used to decipher complex molecular mechanisms underlying disease pathophysiology,develop innovative next generation gene therapy,stem cell-based regenerative therapy,and personalized medicine for corneal and other ocular diseases.In this review we describe latest developments in the field of genome editing,current challenges,and future prospects for the development of personalized genebased medicine for corneal diseases.The gene editing approach is expected to revolutionize current diagnostic and treatment practices for curing blindness.
